#MDCX hashtag - Bluesky

5 days ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate Medicus Pharma (NASDAQ: MDCX) reported independent KOL validation of its Phase 2 SKNJCT-003 SkinJect dataset on March 30, 2026. The 200µg cohort showed ~80% overall response rate, 73% clinical clearance, and 40% histological clearance at Day 57, supporting selection of the 200µg lead dose.Dr. Babar Rao described the results as clinically meaningful and supportive of continued development and regulatory engagement for a potential non-surgical BCC treatment.

#MDCX Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan Medicus Pharma (NASDAQ: MDCX) will host a business update on March 26, 2026, highlighting Phase 2 SkinJect data and AI plans. The 200µg cohort showed an 80% overall response rate (ORR) at Day 57, with 73% clinical clearance and 40% histological complete response.The company plans an End-of-Phase 2 FDA discussion, is advancing an agentic AI clinical platform, and reported $8.7 million in cash at year-end 2025 after raising ~$31.9 million in 2025.

#MDCX Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update Medicus Pharma (NASDAQ:MDCX) reported FY2025 results and a corporate update on March 25, 2026, highlighting a completed 90-patient Phase 2 SkinJect study with up to 73% clearance in the 200µg cohort and strengthened capital via ~$31.9M financing proceeds.FY2025 financials: cash $8.7M, operating expenses $34.4M, net loss $35.4M, and disclosed substantial doubt about going concern; 2026 catalysts include an End-of-Phase 2 FDA meeting and initiation of Teverelix Phase 2b studies.

#MDCX Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst Medicus Pharma (NASDAQ:MDCX) will host a live fireside chat on March 19, 2026 to review positive Phase 2 SkinJect (SKNJCT-003) topline results.Key data: 73% clinical clearance in the 200-µg D-MNA arm at Day 57 versus 38% in the device-only P-MNA control, supporting further development and regulatory discussions.

#MDCX Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

3 weeks ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset Medicus Pharma (NASDAQ: MDCX) reported Phase 2 SKNJCT-003 topline results for SkinJect: the 200-µg cohort achieved 73% clinical clearance and 40% histological clearance at Day 57, versus 38% clinical clearance in the P-MNA arm. The company calls the dataset decision-grade and plans an End-of-Phase-2 meeting with the FDA and to pursue partnering discussions.Medicus also noted UK regulatory approvals to expand SKNJCT-003, completed U.S. enrollment of 90 patients, and recent corporate development activities including an August 2025 MoU and acquisitions.

#MDCX Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

4 weeks ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on

#MDCX Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile Medicus Pharma (NASDAQ: MDCX) amended its LifeArc license for Teverelix, reducing the royalty rate from ~4% to 2% while preserving exclusive worldwide rights, sublicensing ability, IP ownership of Medicus-developed improvements, and operational control.The release cites a ~$6 billion potential combined market for AURr and high cardiovascular‑risk prostate cancer. Parallel updates: SkinJect Phase 2 enrollment completed with 90 patients and topline data expected in Q1 2026, with an end-of-Phase 2 FDA meeting planned in H1 2026.

#MDCX Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women Medicus Pharma (NASDAQ: MDCX) announces Phase 1 e-poster acceptance at AACE 2026 for Teverelix, reporting data from two randomized, placebo-controlled studies in 48 healthy premenopausal women. Key findings: rapid LH/FSH suppression within 24 hours, dose-dependent estradiol suppression with multiple participants in the Barbieri window (30–50 pg/mL), sustained hormone suppression up to two–three weeks at higher doses, stable bone turnover markers, and a favorable safety profile with no drug-related serious adverse events. The company plans Phase 2 genomics-informed endometriosis study and continues SkinJect™ Phase 2 (90 patients enrolled) with topline data expected Q1 2026.

#MDCX Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Lockheed Martin's Revolutionary Joint Command System Enhances Military Drone Operations Lockheed Martin's Skunk Works® and XTEND unveil an integrated system for advanced Command and Control, enhancing drone operations with improved mission execution.

Lockheed Martin's Revolutionary Joint Command System Enhances Military Drone Operations #USA #Lockheed_Martin #Xtend #Palmdale #MDCX

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin Medicus Pharma (NASDAQ: MDCX) completed enrollment of 90 patients in its U.S. Phase 2 trial SKNJCT-003 testing Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal cell carcinoma (BCC) across 9 U.S. sites. The company expects topline results in Q1 2026 and plans to request an End-of-Phase 2 (EOP2) meeting with the FDA in H1 2026. Prior data include a Q1 2025 interim showing >60% clinical clearance in 26 patients and Phase 1 safety/tolerability in 13 participants with 6 complete histologic responses. Recent milestones: positive FDA Type C feedback on a 505(b)(2) pathway, UK regulatory and ethics approvals to expand SKNJCT-003, first patient dosed in SKNJCT-004 UAE, a MoU with HelixNano, acquisition of Antev, and a collaboration with the Gorlin Syndrome Alliance for expanded access.

#MDCX Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement Medicus Pharma (NASDAQ:MDCX) entered a warrant inducement agreement to accelerate exercise of existing Series A and B warrants issued July 14, 2025. The investor agreed to reduce the warrants' exercise price to $1.92 and to immediately exercise all outstanding warrants to buy 2,680,000 common shares for gross proceeds of approximately $5.1 million before fees.In exchange, Medicus will issue unregistered Series C and D warrants to purchase an additional 4,020,000 shares at $2.00 per share, exercisable under similar terms and expiring 5.5 years from issuance; registration of resale of those shares is to be filed with the SEC. Closing is expected on or about December 5, 2025, subject to customary conditions.

#MDCX Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers Medicus Pharma (Nasdaq: MDCX) announced clinical and corporate developments on Nov 24, 2025 focused on next‑generation prostate and skin cancer therapies.Key points: Acquisition of Antev (Aug 2025) advancing Teverelix, a long‑acting GnRH antagonist with Phase 2a data showing 97.5% probability of castrate testosterone suppression (50 patients) and prior FDA written guidance supporting Phase 3 design. The company also reports SkinJect™ microneedle program progress: Phase 1 safety with 6 complete histologic responses (March 2021), ongoing SKNJCT‑003/004 trials, UK regulatory approvals to expand SKNJCT‑003 (Nov 2025), and a GSA collaboration for Expanded Access IND (Oct 2025).

#MDCX Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights Medicus Pharma (NASDAQ:MDCX) reported Q3 2025 corporate and financial updates including clinical progress, an acquisition, patient-access initiatives, and financing activity.Key points: SKNJCT-003 (Phase 2 D-MNA for basal cell carcinoma) has randomized >75% of a 90-patient target and received FDA Type C feedback supporting a 505(b)(2) pathway; UK MHRA/HRA/WREC approvals were received to expand the study and the first patient was treated in a UAE SKNJCT-004 study. Medicus completed the acquisition of Antev (Teverelix) in August 2025. Q3 cash was $8.7M after $10.4M aggregate net proceeds; Q3 operating expenses were $15.4M and net loss was $16.0M.

#MDCX Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome Medicus Pharma (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance to pursue an FDA Expanded Access IND pathway enabling physician‑supervised access to SKINJECT™, an investigational doxorubicin microneedle array for patients with Gorlin syndrome.Key program facts: a Phase 2 study (SKNJCT-003) expanded to 90 subjects with >75% randomized and a reported interim analysis in March 2025 showing >60% clinical clearance; FDA Type C feedback in Sept 2025 indicated a 505(b)(2) regulatory route. The company completed the Antev acquisition in Aug 2025 and runs a 36‑patient SKNJCT-004 study in the UAE.

#MDCX Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets BRISTOL, TN, NY / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.The NASDAQ-listed company is developing Skinject, a dissolvable microneedle array delivering

#MDCX The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

www.stocktitan.net/news/MDCX/the-vanderbilt...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

12 Health Care Stocks Moving In Friday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF), Clearside Biomedical (NASDAQ:CLSD) Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF ) stock increased by 71.8% to $5.86 during Friday's pre-market session. The compan...

#BIAF #BZI-TFM #CLSD #CRNX #DRIO #GUTS #MDCX #NLSP #ORGO #Penny #Stocks

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX) Medicus Pharma (NASDAQ: MDCX) has received coverage initiation from Stonegate Capital Partners following significant strategic developments in Q2 2025. The company has expanded its therapeutic portfolio through the acquisition of Antev Limited, adding dermatology and infectious disease assets to complement its microneedle patch technology for skin cancer.Key developments include a Memorandum of Understanding with Helix Nanotechnologies for co-developing thermostable vaccines, addressing global cold-chain challenges. Financially, MDCX secured an $8.0M non-dilutive debenture financing, with total cash of $9.7M extending runway into 2026.

#MDCX Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

www.stocktitan.net/news/MDCX/stonegate-capi...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited Medicus Pharma (NASDAQ:MDCX) has completed the acquisition of 98.6% of Antev Limited for $2.97 million in cash and 1,603,164 common shares. The deal includes potential additional contingent payments of up to $65 million tied to FDA approvals.Antev is developing Teverelix, a next-generation GnRH antagonist targeting two key indications: Acute Urinary Retention (AURr) and high CV risk Prostate Cancer, representing a combined market opportunity of $6 billion. The company has FDA-approved Phase 2b studies for both indications, with AURr study planning to enroll 390 patients and the prostate cancer study targeting 40 patients.Following the acquisition, industry veteran Patrick J. Mahaffy, former chairman of Antev and ex-CEO of Clovis Oncology, joins Medicus's board of directors.

#MDCX Medicus Pharma Ltd. Completes Acquisition of Antev Limited

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines Medicus Pharma (NASDAQ: MDCX) has signed a non-binding Memorandum of Understanding (MOU) with Helix Nanotechnologies to develop thermostable infectious disease vaccines. The collaboration aims to combine HelixNano's proprietary mRNA vaccine platform with Medicus' Microneedle array (MNA) delivery platform.The companies plan to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines. Initially, they will collaborate on producing clinical-grade mRNA vaccine-loaded MNAs for a Phase 1 clinical bridging study comparing intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.The partnership includes a Sponsored Research Agreement with the University of Pittsburgh under Dr. Lou Falo's direction. HelixNano will supply the mRNA-LNP formulated vaccine material, while Medicus and the University will handle MNA loading and optimization.

#MDCX Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance Poxel (MDCX) has announced major changes to its corporate governance following the filing for insolvency and request for reorganization proceedings with the Court for Economic Activities of Lyon. The company revealed that all current directors have resigned effective July 31, 2025, including CEO Thomas Kuhn.The Board has appointed four new directors: Sophie Jacq Lapointe (new Chairman), Nicolas Trouche (new CEO), Amit Kohli, and Alexandre Bragadir. Among these, Jacq Lapointe and Kohli are considered independent directors. These changes come as part of an agreement with the company's senior creditor, reflecting significant organizational restructuring amid financial challenges.

#MDCX Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance

www.stocktitan.net/news/MDCX/following-the-...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders Medicus Pharma Ltd. (NASDAQ: MDCX) announced the voting results from its Annual and Special Meeting held on July 22, 2025. The company notably welcomed two high-profile additions to its Board of Directors: former Congresswoman Cathy McMorris Rodgers, the first female Chair of the House Committee on Energy & Commerce, and Ajay Raju, a prominent attorney and venture capitalist who previously invested $8M in the company's pre-IPO round.All eight board nominees were elected with overwhelming support, each receiving over 99.8% of votes. Shareholders also approved key measures including the appointment of KPMG LLP as auditors, amendments to company bylaws regarding shareholder meeting quorum requirements, and approval of a Standby Equity Purchase Agreement with YA II PN, Ltd.

#MDCX Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA) Medicus Pharma (NASDAQ: MDCX) has submitted a Type C meeting request to the FDA for October 2025 to discuss their D-MNA (Dissolvable Doxorubicin-containing Microneedle Arrays) development program for treating Basal Cell Carcinoma (BCC).The company's Phase 2 clinical trial SKNJCT-003 is currently ongoing at 9 U.S. sites, with an expanded enrollment to 90 subjects. A March 2025 interim analysis showed promising results with over 60% clinical clearance. The trial evaluates two dose levels (100μg and 200μg) against a placebo control.Additionally, Medicus is conducting the SKNJCT-004 trial in the UAE across four sites, targeting 36 patients. In June 2025, the company announced a definitive agreement to acquire Antev Limited, a UK biotech developing Teverelix for prostate cancer treatment.

#MDCX Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK Medicus Pharma Ltd. (NASDAQ: MDCX) (" Medicus") and Antev Ltd. (" Antev"), a UK-based clinical-stage drug development

#MDCX Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

Medicus Pharma Eyes $250M Equine Cancer Market with FDA Submission for Novel D-MNA Patch Medicus Pharma Ltd. (Nasdaq: MDCX) has submitted a product development plan to the U.S. Food and Drug Administration to advance its doxorubicin-containing micro

#MDCX is targeting the $250M equine cancer market with its novel D-MNA patch, now submitted to the FDA. A big step forward in veterinary oncology innovation!
#MedicusLtd
prismmarketview.com/medicus-phar...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses Medicus Pharma (NASDAQ: MDCX) has submitted a product development plan to the FDA for treating external squamous cell carcinoma (SCC) in horses using their novel Doxorubicin-containing microneedle array (D-MNA) patch. The company received MUMS designation (similar to Orphan Drug status) in December 2024, granting 7-year exclusive marketing rights post-approval. The clinical study SKNJCT-004 will involve 50 horses in a randomized, double-blind trial comparing two D-MNA dose levels against placebo. The market opportunity is estimated at $250 million. The D-MNA technology has shown promising results in human trials, with a Phase 1 study completed in March 2021 showing safety and efficacy, and an ongoing Phase 2 study (SKNJCT-003) demonstrating over 60% clinical clearance in interim analysis. The company is also expanding trials to Europe and UAE, and recently announced plans to acquire Antev Ltd., a UK biotech company developing treatments for prostate cancer.

#MDCX Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

www.stocktitan.net/news/MDCX/medicus-pharma...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

10 months ago